ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 264 for:    inflammatory breast cancer

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02623972
Recruitment Status : Recruiting
First Posted : December 8, 2015
Last Update Posted : May 22, 2018
Sponsor:
Collaborator:
Eisai Inc.
Information provided by (Responsible Party):
Beth Overmoyer, MD, Dana-Farber Cancer Institute

Brief Summary:
This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.

Condition or disease Intervention/treatment Phase
Inflammatory Breast Cancer Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Drug: Eribulin Drug: Adriamycin Drug: Cyclophosphamide Phase 2

Detailed Description:

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied..

Eribulin works by interfering with cancer cell division, growth, and spread.

The goal of this research study is to evaluate inflammatory breast cancer's response to treatment with eribulin followed by AC chemotherapy when given as a preoperative chemotherapy treatment for participants with HER2 negative inflammatory breast cancer.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Eribulin Followed by Doxorubicin and Cyclophosphamide as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Study Start Date : December 2015
Estimated Primary Completion Date : February 2019
Estimated Study Completion Date : February 2023


Arm Intervention/treatment
Experimental: Eribulin
  • Eribulin-Administered via iv, at predetermined dosage and schedule per cycle
  • Two research breast biopsies
  • Adriamycin (doxorubicin) via iv a predetermined dosage and schedule per cycle
  • Cyclophosphamide (AC) via iv a predetermined dosage and schedule per cycle
  • Surgical Removal of the breasts (Mastectomy) and axillary lymph node dissection
  • Radiation Therapy
  • Endocrine Therapy (if applicable)
  • Optional 10 Patient-Optional DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans
Drug: Eribulin
administered IV for 4 cycles
Other Names:
  • Halaven
  • B1939 mesylate

Drug: Adriamycin
administered IV with cyclophosphamide for 4 cycles
Other Name: Doxorubicin

Drug: Cyclophosphamide
administered IV with adriamycin for 4 cycles
Other Names:
  • Cytoxan®
  • Neosar®




Primary Outcome Measures :
  1. Pathologic Complete Response [ Time Frame: 112 Days ]

Secondary Outcome Measures :
  1. Disease Free Survival [ Time Frame: 2 years ]
  2. Time to Treatment Failure [ Time Frame: 2 years ]
  3. Overall Survival [ Time Frame: 2 Years ]
  4. Pathologic disease response at mastectomy will be reported as "residual disease burden (RCB)". [ Time Frame: 2 Years ]
  5. RT-qPCR assessment of gene expression of 10-EMT-related genes and 15-genes involved in modulating vessel phenotype or EC-PVC interactions will be compared following treatment with eribulin. [ Time Frame: 2 Years ]
    The paired expression levels of each gene at the two time points will be summarized graphically and descriptively. Wilcoxon signed rank test will be used to determine if there are any significant changes in the expression level of each gene and the clinical outcome of pCR, DFS, OS, RCB.

  6. To correlate changes in imaging (Ktrans ve, vp, and initial area under the curve (iAUC)) with genomic changes determined on core biopsies of the breast sampled at the same time points. [ Time Frame: 2 Years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

-Participants must have histologically confirmed invasive breast cancer. All histologic subtypes are eligible.

-- Patients must NOT have HER2 positive status based on ASCO/CAP guidelines defined as: IHC 3+ based on circumferential membrane staining that is complete, intense and/or

FISH positive based on one of the three following criteria:

Single-probe average HER2 copy number ≥ 6.0 signals/cell; OR Dual-probe HER2/CEP17 ratio <2.0 with an average HER2 copy number ≥ 6.0 signals/cell; OR Dual-probe HER2/CEP17 ratio ≥2.0

  • Age ≥18 years. Because no dosing or adverse event data are currently available on the use of eribulin in participants <18 years of age, children are excluded from this study
  • ECOG performance status ≤1 (Karnofsky ≥70%, see Appendix A)
  • Participants must have normal organ and marrow function as defined below:

    • leukocytes ≥3,000/mcL
    • absolute neutrophil count ≥1,500/mcL
    • platelets ≥100,000/mcL
    • total bilirubin within normal institutional limits
    • AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal creatinine ≤1.5 × institutional upper limit of normal

      --- OR

    • creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
  • Patients must have the clinical diagnosis of inflammatory breast cancer as evidenced by the onset of signs and symptoms noted below within a 6 month time-period:

    • Erythema of the breast
    • Edema of the skin of the breast
    • Enlargement of the breast
  • Patients must be without evidence of visceral or bone involvement with metastatic cancer on physical exam or any diagnostic study. Extensive nodal involvement is allowed.
  • LVEF > 50% calculated by echocardiogram (ECHO)
  • Patients may have bilateral breast cancer so long as one breast meets criteria for inflammatory breast cancer, and neither breast cancer has received prior therapy.
  • The effects of eribulin on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of eribulin administration.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Both men and women of all races and ethnic groups are eligible for this trial. Because breast cancer predominantly affects females, it is anticipated that male enrollment will be < 5% of the overall study population.

Exclusion Criteria:

  • Participants who are receiving any other investigational agents.
  • Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • Patients with evidence of metastatic disease involvement in viscera or bone.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to eribulin or other agents used in study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study because eribulin is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with eribulin, breastfeeding should be discontinued if the mother is treated with eribulin. These potential risks may also apply to other agents used in this study.
  • HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with eribulin. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.
  • A baseline corrected QT interval of > 470 ms.
  • Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
  • Patients may not have received paclitaxel, doxorubicin, or cyclophosphamide as anti-neoplastic therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02623972


Contacts
Contact: Beth Overmoyer, MD 617-632-6157

Locations
United States, Massachusetts
Brigham and Women's Hospital Active, not recruiting
Boston, Massachusetts, United States, 02215
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Beth Overmoyer, MD    617-632-6157    bovermoyer@partners.org   
Principal Investigator: Beth Overmoyer, MD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
Eisai Inc.
Investigators
Principal Investigator: Beth Overmoyer, MD Dana-Farber Cancer Institute

Responsible Party: Beth Overmoyer, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT02623972     History of Changes
Other Study ID Numbers: 15-292
First Posted: December 8, 2015    Key Record Dates
Last Update Posted: May 22, 2018
Last Verified: May 2018

Keywords provided by Beth Overmoyer, MD, Dana-Farber Cancer Institute:
inflammatory breast cancer
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Additional relevant MeSH terms:
Breast Neoplasms
Inflammatory Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Cyclophosphamide
Liposomal doxorubicin
Doxorubicin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors